Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.

“Clinical and neurobiological findings suggest that¬†cannabinoids¬†and their receptors are implicated in schizophrenia. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects…

Our results suggest a potential therapeutical effect of CBD and rimonabant to treat the emotional processing impairment presented in schizophrenia.

In addition, our results reinforce the anxiolytic profile of CBD.”

http://www.ncbi.nlm.nih.gov/pubmed/22716146

Leave a Reply

Your email address will not be published. Required fields are marked *